Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Clinical trial NCT02983799 · COMPLETED

Trial details

NCT number: NCT02983799
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Start date: 2016-12-22
Primary completion: 2020-12-03
Enrollment: 272

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.